Key Performance
More- Earnings Score: 67
- Momentum Score: 74
- True Yield: N/A
- Financial Health Score: 93
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Environmental DNA Market Set to Surge to USD 5.61 Billion by 2031 with 10.2% CAGR
The global environmental DNA (eDNA) market is expected to grow at a CAGR of 10.2% from 2026 to 2031, driven by non-invasive species detection methods, stricter environmental regulations, and increasing demand for ecosystem health monitoring. North America leads the market with advanced research infrastructure and strong public-private collaborations, while air sampling and climate change impact assessment segments show particularly strong growth potential.
07/06/2026, 4:49 AM • GlobeNewswire
The global molecular biology enzymes, reagents and kits market is projected to grow from USD 27.69 billion in 2025 to USD 70.85 billion by 2035, with a CAGR of 9.68%. Growth is driven by increasing adoption of precision medicine, molecular diagnostics, genomics research, and biotechnology R&D. The US market is expected to reach $23.54 billion and Europe $19.32 billion by 2035, with Asia-Pacific showing the fastest growth.
07/03/2026, 6:48 AM • GlobeNewswire
The global spatial genomics and transcriptomics market is projected to grow from USD 0.60 billion in 2025 to USD 1.90 billion by 2035 at a 12.23% CAGR. Growth is driven by increased adoption of AI-powered spatial biology technologies, precision medicine initiatives, and high-resolution molecular profiling in oncology and translational research. North America is expected to lead with 46% market share, while Asia Pacific shows the highest growth rate at 16.69% CAGR.
06/30/2026, 7:58 AM • GlobeNewswire
The global LIMS market is projected to grow from USD 2.88 billion in 2025 to USD 5.19 billion by 2030, with a CAGR of 12.5%. Growth is driven by increasing demand for laboratory automation, regulatory compliance, cloud-based solutions, and AI integration. North America leads the market, while large enterprises dominate adoption. Key challenges include high maintenance costs and system integration complexities.
06/26/2026, 11:00 AM • GlobeNewswire
Ovarian Cancer Diagnostics Market Size to Reach USD 8.08 Billion by 2035 | SNS Insider
The global ovarian cancer diagnostics market is valued at USD 4.92 billion in 2025 and is projected to reach USD 8.08 billion by 2035, growing at a CAGR of 5.06%. Growth is driven by rising ovarian cancer incidence, increasing adoption of AI-powered imaging, biomarker testing, and precision oncology diagnostics. North America leads with 41.2% market share, while imaging and hospital laboratories dominate their respective segments.
06/19/2026, 5:39 AM • GlobeNewswire
Why Grail Could Be the Sleeper Stock Everyone's About to Notice
Grail, a leader in multi-cancer early detection (MCED) testing, could be poised for significant growth as its Galleri test shows promising clinical trial results. The company awaits FDA approval and potential insurance reimbursement, which could unlock a $50 billion market opportunity. However, the stock remains high-risk due to unprofitability and competition from larger players.
06/08/2026, 5:25 AM • The Motley Fool
Is Grail Stock a Bad-News Buy After Its Recent Pullback?
Grail's stock dropped from a record high of $116 in January to $68 after its NHS trial for the Galleri cancer blood test failed to meet its primary endpoint in February. Despite the setback, the company continues strong direct sales (56,000+ tests in Q1) and expects 22-32% revenue growth this year. The stock trades at 15x sales and could benefit from eventual FDA approval, making it a speculative but potentially worthwhile investment for long-term investors.
06/04/2026, 12:15 PM • The Motley Fool
Global Cervical Cancer Diagnostics Market to Exhibit Growth at a CAGR of ~5% by 2034 | DelveInsight
The cervical cancer diagnostics market is projected to grow from USD 4.4 billion in 2025 to USD 7.1 billion by 2034 at a CAGR of ~5%. Growth is driven by rising cervical cancer prevalence, increasing adoption of advanced diagnostic technologies like HPV testing and AI-powered screening tools, government screening initiatives, and expanding healthcare infrastructure particularly in emerging economies. North America leads the market with 44% share in 2025.
05/14/2026, 1:00 PM • GlobeNewswire
The cancer biomarkers market is projected to grow from USD 23.22 billion in 2026 to USD 35.16 billion by 2031, with a CAGR of 8.65%. Growth is driven by increasing cancer prevalence, rising adoption of personalized medicine, advancements in molecular diagnostics, and expanding use of companion diagnostics. North America leads the market while Asia-Pacific emerges as a high-growth region.
05/14/2026, 3:37 AM • GlobeNewswire
The global colorectal cancer diagnostics and therapeutics market is projected to grow from USD 35 billion in 2025 to USD 73 billion by 2034 at a CAGR of ~9%. Growth is driven by rising colorectal cancer prevalence, increased screening awareness, advancements in non-invasive diagnostics (liquid biopsy, stool-based DNA tests), and emerging targeted therapies and immunotherapies. North America leads with 41% market share, while Asia-Pacific is the fastest-growing region.
05/13/2026, 1:00 PM • GlobeNewswire
The AI in life sciences market is projected to grow from USD 2.2 billion in 2025 to USD 11.5 billion by 2034, driven by accelerated drug discovery, precision medicine adoption, and increasing healthcare data availability. North America leads with 44.78% market share, while Europe and Asia-Pacific show significant growth potential. Major pharmaceutical and technology companies are investing heavily through partnerships and AI-enabled platforms.
05/13/2026, 1:00 PM • GlobeNewswire
The personalized medicine market is projected to grow from USD 524 billion in 2025 to USD 1 trillion by 2034, driven by advances in genomics, AI-powered diagnostics, and targeted therapies. North America leads the market with 41% share, while Asia-Pacific emerges as a key growth engine. Major pharmaceutical and biotech companies are investing heavily in precision medicine solutions across oncology, rare diseases, and chronic conditions.
05/11/2026, 1:00 PM • GlobeNewswire
The global DNA microarray market is expected to grow from USD 2.5 billion in 2025 to USD 4.7 billion by 2034 at a CAGR of ~7%. Growth is driven by rising demand for genomic research, personalized medicine, early disease diagnosis, and increasing prevalence of cancer and genetic disorders. North America leads the market with 41.39% share, while Asia-Pacific emerges as a key growth contributor.
05/06/2026, 1:00 PM • GlobeNewswire
The global Targeted DNA RNA Sequencing Market was valued at USD 8.6 billion in 2025 and is projected to reach USD 46.9 billion by 2035, growing at an 18.5% CAGR. Growth is driven by government genomic surveillance initiatives, pharmaceutical biomarker discovery, and rising demand for precision medicine. North America leads in market share while Asia Pacific shows the highest growth rate.
05/04/2026, 3:30 PM • GlobeNewswire
The omics-based clinical trials market is experiencing robust growth, expanding from $31.71 billion in 2025 to $34.49 billion in 2026 with an 8.8% CAGR, and projected to reach $47.78 billion by 2030. Growth is driven by increasing demand for personalized medicine, genomics advancements, AI-enabled patient recruitment, and biomarker-driven trial designs. North America leads the market while Asia-Pacific shows rapid expansion potential.
04/24/2026, 4:59 AM • GlobeNewswire
Peers
Statistics
MoreInformation as of 07/13/2026
Company Profile
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. The company has a collaboration with Labcorp Holdings Inc. for the development of oncology treatments through applications of sequencing solutions across the healthcare ecosystem; and strategic collaboration with Integrated DNA Technologies to enable a DRAGEN, secondary analysis pipeline for IDT xGena, FFPE and cfDNA next generation sequencing (NGS) library preparation with custom panels, delivering an integrated, end-to-end solution for somatic oncology research. It also has a data partnership with Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare disease. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.